33
Participants
Start Date
August 22, 2016
Primary Completion Date
August 11, 2021
Study Completion Date
November 22, 2022
Hypofractionated Stereotactic Irradiation
Hypofractionated Stereotactic Irradiation (HFSRT) prior to nivolumab.
Nivolumab
Nivolumab intravenously (IV): 240 mg every (q) 3 weeks x 4 months followed by 480 mg X 4 months.
Bevacizumab
Bevacizumab intervenously (IV): 15 mg/kg every (q) 3 weeks when given with Ipilumumab and Nivolumab combination. Dose changed to 10mg/kg every 2 weeks when given with Nivolumab only.
Ipilimumab
Ipilimumab 1mg/kg intervenously (IV) 200 mg (5 mg/mL) every (q) 3 weeks for 4 months.
H. Lee Moffitt Cancer Center and Research Institute, Tampa
Ohio State University Comprehensive Cancer Center, Columbus
H. Lee Moffitt Cancer Center and Research Institute
OTHER